相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy
Alison Taylor et al.
CANCER RESEARCH (2018)
Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells
Janna Krueger et al.
IMMUNITY (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses
Alison Taylor et al.
IMMUNITY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
TCR and CD28 activate the transcription factor NF-κB in T-cells via distinct adaptor signaling complexes
Youg Raj Thaker et al.
IMMUNOLOGY LETTERS (2015)
PDK1 controls upstream PI3K expression and PIP3 generation
A. M. Dieterle et al.
ONCOGENE (2014)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
The Strength of T Cell Receptor Signal Controls the Polarization of Cytotoxic Machinery to the Immunological Synapse
Misty R. Jenkins et al.
IMMUNITY (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death
Helga Schneider et al.
PLOS ONE (2008)
A blocking Anti-CD28-specific antibody induces lonq-term heart allograft survival by suppression of the PKCθ-JNK signal pathway
Mei-Shiang Jang et al.
TRANSPLANTATION (2008)
Peptides targeting protein kinases: Strategies and implications
Oksana Kaidanovich-Beilin et al.
PHYSIOLOGY (2006)
TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1
Joanne E. Wood et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
A dynamic view of the immunological synapse
ML Dustin
SEMINARS IN IMMUNOLOGY (2005)
CD28 superagonists:: Mode of action and therapeutic potential
T Hünig et al.
IMMUNOLOGY LETTERS (2005)
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-κB subunits on IL-8 and Bcl-xL gene promotors
B Marinari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
GSK3 inhibitors: Development and therapeutic potential
P Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling
CE Rudd et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Independent CD28 signaling via VAV and SLP-76:: a model for in trans costimulation
CE Rudd et al.
IMMUNOLOGICAL REVIEWS (2003)
A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS)
Y Harada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
New regulatory co-receptors: inducible co-stimulator and PD-1
T Okazaki et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation
M Diehn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
A Martinez et al.
MEDICINAL RESEARCH REVIEWS (2002)
CD28 signaling via VAV/SLP-76 adaptors: Regulation of cytokine transcription independent of TCR ligation
M Raab et al.
IMMUNITY (2001)
T-cell regulation by CD28 and CTLA-4
ML Alegre et al.
NATURE REVIEWS IMMUNOLOGY (2001)
Cutting edge:: Distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL
JS Burr et al.
JOURNAL OF IMMUNOLOGY (2001)
Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation
Y Harada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Transplantation and the CD28/CTLA4/B7 pathway
M Alegre et al.
TRANSPLANTATION PROCEEDINGS (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation
F Michel et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
